<DOC>
	<DOCNO>NCT01613053</DOCNO>
	<brief_summary>Continuation drug supply Chinese patient CAMN107DBR01study termination .</brief_summary>
	<brief_title>Continuation Drug Supply Chinese Patients After CAMN107DBR01study Termination</brief_title>
	<detailed_description>Five patient treatment imatinib derive clinical benefit CAMN107DBR01 study termination write informed consent obtain enter trial , five patient receive Glivec ( 8oomg per day ) treatment tumor progression [ RECIST guideline , version 1.0 ] , unacceptable toxicity , death withdrawal consent .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<criteria>Five patient treatment imatinib derive clinical benefit CAMN107DBR01 study termination write informed consent obtain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Gastrointestinal Stromal Tumor , GIST</keyword>
</DOC>